Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05568459
- Locations
- 🇺🇸
University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
- Conditions
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT05557591
- Locations
- 🇺🇸
The Oncology Institute of Hope and Innovation, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Weill Cornell Medical College, New York, New York, United States
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05546957
- Locations
- 🇬🇧
LabCorp CRU, Leeds, West Yorkshire, United Kingdom
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05519475
- Locations
- 🇺🇸
The Institute for Liver Health II LLC DBA Arizona Liver Health - Peoria, Peoria, Arizona, United States
🇺🇸Ark Clinical Research - Long Beach, Long Beach, California, United States
🇺🇸Synergy Healthcare, LLC, Bradenton, Florida, United States
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05505448
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Belgium
A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT05481333
- Locations
- 🇧🇪
Drug Research Unit Gent, Gent, Belgium
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT05430919
- Locations
- 🇨🇦
Inflamax Research Limited DBA Cliantha Research, Mississauga, Ontario, Canada
🇨🇦Kingston General Health Research Institute, Kingston, Ontario, Canada
🇨🇦Clinique Specialisee en Allergie de la Capitale, Quebec City, Quebec, Canada
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5311
- Registration Number
- NCT05423327
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Velocity Clinical Research, Gardena, California, United States
🇺🇸UCSD Health System, La Jolla, California, United States
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT05394116
- Locations
- 🇫🇷
Hôpital Lapeyronie, Montpellier, France
🇯🇵Kyushu University Hospital, Fukuoka, Japan
🇧🇷Hospital Israelita Albert Einstein, Sao Paulo, Brazil
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT05363319
- Locations
- 🇫🇷
Investigational Site Number: 250-004, Marseille, Bouches-du-Rhône, France
🇩🇪Investigational Site Number: 276-012, Georgsmarienhütte, Niedersachsen, Germany
🇩🇪Investigational Site Number: 276-009, Troisdorf, Nordrhein-Westfalen, Germany